Back to top
more

VERADIGM INC (MDRX)

(Delayed Data from OTC)

$9.85 USD

9.85
143,417

0.00 (0.00%)

Updated Jul 12, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Technology Services

Better trading starts here.

Zacks News

Zacks.com featured highlights include Asbury Automotive Group, Allscripts Healthcare Solutions, HarleyDavidson, AGCO and CBRE Group

Asbury Automotive Group, Allscripts Healthcare Solutions, HarleyDavidson, AGCO and CBRE Group are included in this blog.

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Phibro (PAHC) Q2 Earnings Surpass Estimates, 2022 View Up

Phibro (PAHC) reports better-than-expected earnings for the fiscal second quarter. Robust performances by the Animal Health and Mineral Health segments drove the top line.

Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Down

Strength in Life Sciences segment driven by a recovery in routine testing drove Bio-Rad (BIO) top line in the fourth quarter.

Illumina (ILMN) Q4 Earnings Top Estimates, Gross Margin Up

Record shipments for both clinical and research with strength in oncology testing, genetic disease testing, and population genomics drove Illumina (ILMN) Q4 revenues.

LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Down

LabCorp (LH) reports better-than-expected results for the fourth quarter, with solid contributions from the Drug Development business driving the top line.

Here's Why You Should Retain Abbott (ABT) Stock For Now

Investors continue to be optimistic about Abbott (ABT) owing to the strength in its diagnostics business.

STERIS (STE) Q3 Earnings Surpass Estimates, Revenues Miss

STERIS (STE) reports better-than-expected earnings for the third quarter of fiscal 2022 and robust segmental growth driving the top line.

Baxter (BAX) Hits 52-Week High: What's Aiding the Stock?

Investors are optimistic about Baxter's (BAX) strong product portfolio.

What's in the Cards for Henry Schein (HSIC) in Q4 Earnings?

Solid demand in the global dental market along with an increase in COVID-19 test demand are likely to have contributed to Henry Schein's (HSIC) Q4 performance.

Sanghamitra Saha headshot

5 Top Stocks Likely to Beat Earnings Estimates

These top-ranked stocks are likely to beat on bottom line in their next releases.

Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?

Ecolab's (ECL) fourth-quarter results are likely to reflect continued strength across its business segments.

CVS Health (CVS) Q4 Earnings Beat Estimates, Margins Up

Strength in all three operating segments drove CVS Health's (CVS) revenues in the fourth quarter of 2021.

QIAGEN (QGEN) Q4 Earnings Surpass Estimates, Margins Down

High demand for COVID-19 test products and improving trends in the non-COVID portfolio drove QIAGEN's (QGEN) fourth-quarter revenues.

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

Increase in number of orders for Cologuard and new study findings supporting the Oncotype DX are likely to have contributed to Exact Sciences' (EXAS) Q4 performance.

Haemonetics (HAE) Q3 Earnings Top Estimates, Revenues Miss

Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.

Zimmer Biomet (ZBH) Q4 Earnings Miss Estimates, Margins Down

According to Zimmer Biomet (ZBH), both Q4 net sales and earnings metrics are negatively impacted by China VBP in Knees, Hips and S.E.T. product categories.

Why AllScripts (MDRX) is Poised to Beat Earnings Estimates Again

AllScripts (MDRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

Sustained momentum with respect to inpatient dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the fourth quarter despite the ongoing pandemic-led business challenges.

Cardiovascular Systems' (CSII) Q2 Earnings Lag Estimates

Cardiovascular Systems (CSII) exhibits a robust performance by its worldwide coronary franchise despite challenging business climate.

Surging Earnings Estimates Signal Upside for AllScripts (MDRX) Stock

AllScripts (MDRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Allscripts (MDRX) Reports Solid Preliminary Q4 Revenues

Allscripts' (MDRX) revenue growth in the fourth quarter is likely to have been boosted by solid segmental performances.

Is AllScripts Healthcare (MDRX) Outperforming Other Medical Stocks This Year?

Here is how AllScripts Healthcare (MDRX) and Pharvaris N.V. (PHVS) have performed compared to their sector so far this year.

Here's Why You Should Retain Allscripts (MDRX) Stock For Now

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and various innovation milestones.

Allscripts' (MDRX) Services Leveraged by Next Level Urgent Care

Allscripts' (MDRX) Touchworks platform and Microsoft Azure hosting & services will be implemented across all Next Level Urgent Care's sites in Houston.